CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Química de São Carlos (IQSC) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Chemistry - Oswaldo Cruz (1981), MSc in Organic Chemistry (1987) and a Ph.D. in Organic Chemistry from the University of São Paulo (1991). In 1995, held a postdoctoral fellowship in Medicinal Chemistry under the supervision of Michael Tute, Pfizer / University of Kent, UK. In 2003, obtained the title of Associate Professor at the Institute of Chemistry, USP. He is currently full professor at the Institute of Chemistry of São Carlos, University of São Paulo. Has experience in the area of #8203;#8203;chemistry, with an emphasis on Medicinal Chemistry, acting on the following topics: hypothesis driven molecular design, machine learning and biocalorimetry. He is currently a member of the editorial board of the Chemical Biology Drug Design and also Associate Editor of Frontiers in Drug Discovery - Anti-Infective Agents. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Our extensive efforts to develop inhibitors for human cathepsin L and SARS-CoV-2 main protease (Mpro) have led to the identification of a set of antiviral agents exhibiting superior efficacy compared to nirmatrelvir (synthesized in our laboratory and dubbed Neq1183). Preliminary studies on cytochrome P450 enzymes revealed that Neq1184 shows no activity, indicating that it is a superior ca…
Despite the FDA approval of Paxlovid and Molnupiravir and the hope that they will act on the omicron strain - both are effective on the delta strain; there is still room for nirmatrelvir optimization. Considering the excellent results obtained through the FAPESP project #2020/04653-2, we will continue the in vitro and in vivo assays of the best-identified antivirals (Neq1119, Neq1167, Neq…
The current worldwide outbreak of the coronavirus with a pandemic declared by the World Health Organization (WHO) is beginning to strike in Brazilian lands. This pandemic urged us to start an emergency project in the search for new proteases inhibitors of the main coronavirus protease (SARS Cov-2 Mpro) as antiviral agents acting on the coronavirus. Several cysteine protease inhibitors (CP…
(Only some records are available in English at this moment)
Despite the success in the application of vaccines to combat the new coronavirus and the end of the pandemic state of emergency announced by the WHO, studies regarding SARS-CoV-2, as well as the development of drugs to treat COVID-19, are still ongoing. of extreme relevance for medicinal chemistry and public health, given the potential economic and social threats that a new variant can ca…
New treatments for neglected tropical diseases are needed, and peptidomimetic compounds, which inhibit cysteine proteases and are more stable than peptides, show great promise as new oral drugs, more effective and with fewer side effects than current treatments. Recent studies have shown that some compounds of this class, despite having great inhibitory activity for enzymes, have not been…
The current outbreak of the COVID-19 and its subsequently classification of pandemic have led everyone's attention. Considering the fact that there is no treatment for SARS-CoV and MERS-CoV, it is urgent the development of a treatment that is able to act on the main protease of the SARS-CoV-2. This project focuses on the synthesis of novel inhibitors that acts on SARS-CoV-2 Mpro and also …
(Only some records are available in English at this moment)
The pandemic of COVID-19 has drawn everyone's attention. Unfortunately, since the appearance of the SARS and MERS viral infections in the 2000s, no treatments have been developed thus far. Therefore, it is urgent the production of a molecule to serve as a treatment that can act against SARS-CoV-2, the causative agent of COVID-19. This project aims at synthesizing novel inhibitors that can…
Cruzain is an established target for the identification of novel trypanocidal agents, but how good are in vitro/in vivo correlations for active compounds? This project aims at the development of computational models for the prediction of the properties of cruzain inhibitors that are Trypanosoma cruzi killers. We will systematically analyze structure-activity relationships (SARs), visualiz…
The proponent is a FAPESP fellow (process 2013/01128-0), which is linked to the thematic project 2013/18009-4 under my supervision and presents this project of work to request a BEPE type scholarship to the University of Washington in Seattle, USA, under the supervision of Prof. Michael Gelb. Our best cruzain inhibitors (sub-micromolar) kill T. cruzi in varying concentrations and several …
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 22 / 19 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 26 / 23 | Completed scholarships in Brazil |
| 4 / 4 | Completed scholarships abroad |
| 54 / 48 | All research grants and scholarships |
| Associated processes | |